We scan new podcasts and send you the top 5 insights daily.
Sorting public dataset molecules by molecular weight alone matches top machine learning models in binding prediction. This correlation arises purely from chemist behavior: as a starting molecule shows activity, chemists iteratively tack on functional groups to optimize affinity and solubility, inflating the size of active compounds.
To evolve AI from pattern matching to understanding physics for protein engineering, structural data is insufficient. Models need physical parameters like Gibbs free energy (delta-G), obtainable from affinity measurements, to become truly predictive and transformative for therapeutic development.
Modeling small molecules might seem easier than large proteins, but the chemical search space for drug-like small molecules is astronomical (10^60). This vastness makes finding a correct binding match computationally far more complex than for more specific protein-protein interactions.
Unlike traditional methods that simulate physical interactions like a key in a lock, ProPhet's AI learns the fundamental patterns governing why certain molecules and proteins interact. This allows for prediction without needing slow, expensive, and often impossible physical or computational simulations.
Models trained on public repositories like ChEMBL achieve high accuracy merely by predicting the creator of a molecule from its structure rather than learning chemical physics. Replacing molecular formulas with a vector indicating the probability of the chemist author yields identical predictive performance on target activity.
Because DNA encoded libraries are built combinatorially from building blocks, millions of molecules differ by only one or two changes. This structured variation enables machine learning models to isolate exactly which chemical fragments drive target binding while keeping the rest of the molecule constant.
Despite testing millions of compounds, high-throughput screening methods suffer from enormous false-positive rates. The actual predictive value for a re-synthesized molecule is extremely low, creating an opening for high-fidelity AI models to provide cleaner, more reliable predictions.
In a 2,000-team Kaggle challenge using a 4-billion interaction dataset, models performed adequately when test molecules shared building blocks or core hubs with the training set. However, when evaluated against completely orthogonal chemical libraries with distinct chemistry, no model beat random chance.
Conventional molecular complexity metrics fail because they treat molecules as static objects. In reality, a molecule's properties like solubility or bioactivity are emergent from its dynamic motion, which changes based on its environment (e.g., temperature, solvents), much like a stock's behavior changes across different markets.
Unlike fields with vast training data like image recognition, effective drug discovery has too few successful examples for AI to learn from alone. To be useful, AI models must be explicitly taught the foundational principles and complex rules of medicinal chemistry that human experts use.
The immediate goal for AI in drug design is finding initial "hits" for difficult targets. The true endgame, however, is to train models on manufacturability data—like solubility and stability—so they can generate molecules that are already optimized, drastically compressing the development timeline.